347 related articles for article (PubMed ID: 33221023)
1. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
Chambers LM; Jia X; Rose PG; AlHilli M
Gynecol Oncol; 2021 Feb; 160(2):405-412. PubMed ID: 33221023
[TBL] [Abstract][Full Text] [Related]
2. Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer.
Tobias CJ; Chen L; Melamed A; St Clair C; Khoury-Collado F; Tergas AI; Hou JY; Hur C; Ananth CV; Neugut AI; Hershman DL; Wright JD
JAMA Netw Open; 2020 Dec; 3(12):e2028612. PubMed ID: 33295973
[TBL] [Abstract][Full Text] [Related]
3. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
5. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.
Leiserowitz GS; Lin JF; Tergas AI; Cliby WA; Bristow RE
Int J Gynecol Cancer; 2017 May; 27(4):675-683. PubMed ID: 28328580
[TBL] [Abstract][Full Text] [Related]
6. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
8. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
Wilkinson-Ryan I; Frolova AI; Liu J; Stewart Massad L; Thaker PH; Powell MA; Mutch DG; Hagemann AR
Int J Gynecol Cancer; 2015 Jan; 25(1):63-8. PubMed ID: 25365590
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
10. Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.
Jooya ND; Ciccone MA; Brunette LL; Pham HQ; Yessaian AA; Muderspach LI; Roman LD; Matsuo K
Gynecol Oncol; 2022 Jun; 165(3):428-436. PubMed ID: 35459549
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
12. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
Onda T; Satoh T; Ogawa G; Saito T; Kasamatsu T; Nakanishi T; Mizutani T; Takehara K; Okamoto A; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Kanao H; Watanabe Y; Yamamoto K; Yaegashi N; Kamura T; Yoshikawa H;
Eur J Cancer; 2020 May; 130():114-125. PubMed ID: 32179446
[TBL] [Abstract][Full Text] [Related]
13. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.
Nakamura K; Kitahara Y; Nishimura T; Yamashita S; Kigure K; Ito I; Kanuma T
World J Surg Oncol; 2020 Aug; 18(1):200. PubMed ID: 32791996
[TBL] [Abstract][Full Text] [Related]
14. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
Matsuo K; Matsuzaki S; Nusbaum DJ; Maoz A; Oda K; Klar M; Roman LD; Sood AK
Gynecol Oncol; 2021 Jan; 160(1):32-39. PubMed ID: 33196436
[TBL] [Abstract][Full Text] [Related]
15. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
Persenaire C; Pyrzak A; Barber EL
J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.
Liu YL; Filippova OT; Zhou Q; Iasonos A; Chi DS; Zivanovic O; Sonoda Y; Gardner GJ; Broach VA; O'Cearbhaill RE; Konner JA; Aghajanian C; Long Roche K; Tew WP
J Gynecol Oncol; 2020 Jan; 31(1):e17. PubMed ID: 31833259
[TBL] [Abstract][Full Text] [Related]
17. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
18. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
19. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
[TBL] [Abstract][Full Text] [Related]
20. Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer.
Wright JD; Huang Y; Melamed A; Albright BB; Hillyer GC; Previs R; Hershman MSDL
Gynecol Oncol; 2021 Sep; 162(3):599-605. PubMed ID: 34158181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
